Conference Coverage

Galcanezumab benefits patients with migraine and medication overuse


 

REPORTING FROM AHS 2019

Galcanezumab reduced medication overuse

Compared with placebo, both doses of galcanezumab significantly decreased mean monthly migraine headache days in patients with baseline medication overuse. In the EVOLVE studies, this endpoint decreased by 2.71 in the placebo group, 6.26 in the galcanezumab 120-mg group, and 5.77 in the galcanezumab 240-mg group. In REGAIN, the reductions were 2.25 in the placebo group, 4.78 in the galcanezumab 120-mg group, and 4.51 in the galcanezumab 240-mg group. The effect size was higher in patients who were overusing medications, compared with those who were not, said Dr. Aurora. “This is clinically relevant, because most of us ... had this belief that patients who were overusing medications may be more treatment-resistant to prevention.”

In addition, galcanezumab was associated with significantly lower rates of average monthly medication overuse, compared with placebo. In the EVOLVE studies, the average rate of monthly medication overuse was 15.9% for the placebo group, 6.2% for the galcanezumab 120-mg group, and 7.9% for the galcanezumab 240-mg group. In REGAIN, the average rate of monthly medication overuse was 40.6% in the placebo group, 24.3% in the galcanezumab 120-mg group, and 23.1% in the galcanezumab 240-mg group. About 85% of patients with episodic migraine and medication overuse had a reduction in medication overuse, and approximately 50% of patients with chronic migraine and medication overuse had a reduction in medication overuse, said Dr. Aurora.

Dr. Aurora and coinvestigators are employees of Eli Lilly, which developed galcanezumab and funded the EVOLVE and REGAIN studies.

SOURCE: Aurora S et al. AHS 2019. Abstract IOR07.

Pages

Recommended Reading

Green light therapy: A stop sign for pain?
Journal of Clinical Outcomes Management
Mindfulness-based stress reduction reduces migraine frequency
Journal of Clinical Outcomes Management
Can mindfulness-based cognitive therapy treat migraine?
Journal of Clinical Outcomes Management
Nearly 20% of migraineurs use opioids for migraine
Journal of Clinical Outcomes Management
Medication overuse prevalent among U.S. migraine patients
Journal of Clinical Outcomes Management
Posttraumatic headache may be associated with reduced pain thresholds
Journal of Clinical Outcomes Management
Quarterly intravenous eptinezumab prevents migraine
Journal of Clinical Outcomes Management
Treatment of episodic cluster headache deviates from recommendations
Journal of Clinical Outcomes Management
Asthma hospitalization in kids linked with doubled migraine incidence
Journal of Clinical Outcomes Management
Pediatric, adolescent migraine treatment and prevention guidelines are updated
Journal of Clinical Outcomes Management